Distant metastasis of undifferentiated carcinoma of nasopharyngeal type

Onkologie

Volumn 31, Issue 11, 2008, Pages 574-575

  Tao, Yungan ^a   Bidault, François ^a   Bosq, Jacques ^a   Bourhis, Jean ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; SORAFENIB;

BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EDITORIAL; ENDEMIC DISEASE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; NASOPHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOFREQUENCY ABLATION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA;

ANESTHETICS, COMBINED; CARCINOMA; HUMANS; LIVER NEOPLASMS; NASOPHARYNGEAL NEOPLASMS;

EID: 58849117606     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000164934     Document Type: Editorial

References (18)

1. Guigay J, Temam S, Bourhis J, Pignon JP, Armand JP: Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy. Ann Oncol 2006;17 Suppl 10:x304-307.
2. Tao Q, Chan AT: Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007;9:1-24.
3. Cvitkovic E, Bachouchi M, Boussen H, Busson P, Rousselet G, Mahjoubi R, Flores P, Tursz T, Armand JP, Azli N: Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J Clin Oncol 1993;11:2434-2442.
4. Lee AW, Law SC, Foo W, Poon YF, Cheung FK, Chan DK, Tung SY, Thaw M, Ho JH: Retrospective analysis of patients with nasopharyngeal carcinoma treated during 1976-1985: survival after local recurrence. Int J Radiat Oncol Biol Phys 1993;26:773-782.
5. Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D, Sze WM, Law CK, Leung TW, Chan AT: Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 2004;101:300-306.
6. Kao CC,Yu CP, Liu YC,Yu JC,Hsieh CB: Unusual presentation of cystic liver metastases from nasopharyngeal carcinoma. Onkologie 2008;31:635-636.
7. Liu FY, Lin CY, Chang JT, Ng SH, Chin SC, Wang HM, Liao CT, Chan SC, Yen TC: 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med 2007;48:1614-1619.
8. Guigay J: Advances in nasopharyngeal carcinoma. Curr Opin Oncol 2008;20:264-269.
9. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ: Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996;77:2423-2431.
10. Weitz J, Blumgart LH, Fong Y, Jarnagin WR, D'Angelica M, Harrison LE, DeMatteo RP: Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg 2005;241:269-276.
11. Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet 2005;365:2041-2054.
12. Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, Eschwege F, Armand JP, Simon J, Cvitkovic E: Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000;18:1324-1330.
13. Ma BB, Chan AT: Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 2005;103:22-31.
14. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, Mueser M, Amellal N, Lin X, Chang AY: Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-3576.
15. Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J, Au GK: Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008;30:863-867.
16. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O, Chen EX: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25:3766-3773.
17. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S: Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005;23:8942-8949.
18. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE: Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005;105:1898-1904.